INTRODUCTION
Currently, 5.4 million people in the UK are receiving treatment for asthma [1] , which is associated with a substantial economic burden: the annual National Health Service (NHS) expenditure associated with treating and caring for asthma patients, in terms of drug costs, hospital admissions and general practitioner (GP) visits, was estimated to be approximately £1 billion in the UK [1] .
There are a number of treatments available for asthma patients, and combination inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) inhalers are recommended for the treatment of patients with asthma who are not controlled with ICS alone [2] . These combination inhalers are as effective at delivering the drug as individual component inhalers but may provide additional benefits in terms of safety (by ensuring the LABA component is not taken without the ICS component) and patient adherence [3, 4] . There are two main types of combination ICS/ LABA inhaler devices: the pressurized metered-dose inhaler (pMDI) and dry powder inhaler (DPI). Of these two main options, there may be benefits of using pMDIs over DPIs. For example, a recent study demonstrated that pMDIs, as opposed to DPIs, are associated with increased adherence in clinical practice, fewer exacerbations and lower health costs [5] . overall ICS/LABA units prescribed for patients with an asthma diagnosis [6] .
Prior to the introduction of FP/FORM, a budget impact model was developed to evaluate the impact for the NHS of using FP/ FORM as an alternative treatment to FP/SAL [7] .
The comparable efficacy of FP/FORM to FP/SAL had been previously demonstrated in patients aged C18 years with persistent asthma for C6 months in an open-label, randomized, active-controlled, parallel-group, multicenter, Phase III non-inferiority study [8, 9] . Based on projected FP/FORM uptake scenarios, the previous model demonstrated that switching from FP/SAL to FP/FORM could result in savings to the NHS [7] . Since the introduction of FP/ FORM to the UK market, data demonstrating the effectiveness and resource use impact of FP/ FORM in real-world settings have become available, which may impact upon the previously modeled outputs [10] . The real-world data showed that patients who switched from FP/SAL to FP/FORM had fewer asthma consultations (with or without prescription of oral steroids) (1.4 for FP/FORM versus 1.8 for FP/SAL; p = 0.001) and also confirmed that FP/FORM is non-inferior to FP/ SAL in terms of preventing severe exacerbations [10] .
Aims
The aims of this update to the budget impact analysis were twofold: to update the existing budget impact model with prescription volume data since the introduction of FP/FORM to the UK market, and to compare the results of the budget impact model base-case with newly available real-world evidence to evaluate the use of FP/FORM in clinical practice, as compared to FP/SAL.
METHODS

Update of Budget Impact Model
The full methodology of the existing budget impact model has been published previously [7] . In addition to the previous analyses, the updated model also considers the inputs of adverse events (AEs) within the base-case scenario, instead of inclusion in a scenario analysis. Furthermore, the update considers real-world evidence, which has become available since FP/FORM entered the market.
Comparators
As with the previous model, Seretide Evohaler (FP/SAL) was considered to be the most appropriate comparator to FP/FORM for analysis of the budget impact to the NHS as it is in the same pMDI device type [7] . Due to differences in device handling, it was assumed patients were less likely to switch between DPIs and pMDIs, thus DPIs were excluded from the analysis. As discussed in the previous publication [7] Drug-related costs included drug acquisition costs, monitoring costs, and administration costs; these were based on product labels, UK reference costs and global initiative for asthma (GINA) guidelines. AE-associated costs were based on rates from the head-to-head non-inferiority study of FP/FORM versus FP/ SAL [8] , a GP visit and a 1 week course of antibiotics (Augmentin) for infections and infestations. It was assumed that monitoring costs would not differ between pMDIs as GINA guidelines (2015) state that patients should be seen 1-3 months after initiation of any treatment and every 3-12 months after that [2] . To be consistent with the previous budget impact analysis [7] and to be in line with the new GINA guidelines, it was assumed that patients were seen four times per year and costed according to the Personal Social Services Research Unit (PSSRU) for GP visits (Table 1 ) [14] . However, as there is uncertainty over the level of consultations due to the broad range given in the GINA guidelines, this assumption was tested using the real-world data, which reported the average number of asthma consultations, in a scenario analysis. AE rates were based on infestations and infections data from a 12-week head-to-head non-inferiority trial FP/FORM (13.9%) versus FP/SAL (12.9%) (the two treatment groups overall had similar safety and tolerability profiles, and infections and infestations were the most commonly reported AE) [8] . The cost per AE was assumed to be equivalent between treatments and based on one GP visit (costed according to PSSRU) and one course of Augmentin (costed according to BNF, October 2015) [13, 14] . Costs were estimated according for 12 weeks and extrapolated to 1 year based on the assumption that AEs would continue at the same rate throughout the year (Table 1) .
Budget Impact Analysis
Cost Per Person Year
Costs per person year were calculated based on the sum of the total drug-related and monitoring costs (Table 1) . Table 1 ): This scenario analysis was applied to each of the prescription volume analyses described above.
Annual Costs for the NHS
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RESULTS
Base-Case Analysis
Cost Per Person Year Annual drug acquisition costs were lower with FP/FORM (£397) than with FP/SAL (£508), while annual administration training (£13) and monitoring costs (£184) were the same for both combination therapies. AE costs were very slightly higher with FP/FORM (£31) than FP/SAL (£29). The cost per person year based on the current prescription volume data was £109 less with FP/FORM (£625) than with FP/SAL (£734) (Fig. 1) .
Cost to NHS
Annual costs to NHS are presented in Fig. 2 . However, with 0% prescription of FP/FORM, the budget impact at CCG level was calculated at 12%, 25%, 50%, 100% prescription volume shares, respectively.
Scenario Analyses
Scenario 1: Real-World Data
This scenario considered monitoring cost data from a UK real-world study [10] . In comparison to the base-case, inclusion of real-world data resulted in decreased costs to the NHS in all prescription volume scenarios considered (Fig. 2) . This was driven by the differences in the monitoring costs. TBI to the NHS decreased from £179.8M at a 12% FP/FORM prescription volume to £175.1M, £165.9M and £147.3M at 25%, 50% and 100% FP/FORM prescription volume, respectively.
When FP/FORM prescription volume was decreased to 0%, the total cost to the NHS increased to £184.4M. The savings compared to no use of FP/FORM were £4.6M, £9.3M, £18.5M, £37.1M at 12%, 25%, 50%, 100% prescription volume shares, respectively.
Using the current prescription volumes, cost per person year was calculated at £505 for FP/ FORM and £632 for FP/SAL, saving £127 with FP/FORM (Fig. 1) . When considering data at CCG level at the current prescription volumes, the budget impact was calculated as £696. 
DISCUSSION
This study demonstrates that the use of FP/ FORM as an alternative to FP/SAL can result in costs predicted by the RCT data, subject to a successful switch [10] . The difference in costs between the base-case and the real-world scenario was driven by monitoring costs. was £64 lower for FP/FORM), which is in line with the findings of our analysis [18] .
Another recent study in Spain noted that when comparing the price of FP/FORM with other combinations of ICS/LABA, the price of FP/FORM was significantly lower [19] . Furthermore, over the first 3 years, the Spanish National Health Service is expected to save nearly €4.4 million from its pharmacy budget with the introduction of FP/FORM for the treatment of moderate to severe asthma [19] . Furthermore, a non-interventional study on safety and effectiveness in Germany reinforced the findings from the clinical trials by demonstrating that FP/FORM improves lung function, asthma control, and asthma related quality of life in a real-world setting: there was a statistically significant improvement compared with baseline in asthma control (as measured by the Asthma Control Test) of patients being treated with FP/FORM over a 3-month period, and there were also improvements seen in terms of quality of life and other secondary efficacy measures [20] .
As noted, our analysis demonstrates that an increased uptake of FP/FORM can result in overall cost savings to the NHS without adversely affecting clinical outcomes; there have been several studies comparing FP/FORM with FP/SAL [8, 9] and Phase III clinical trials have demonstrated that FP/FORM is at least as effective as, and has a faster onset of action, than FP/SAL [8, 9] . In addition, FP/FORM has been recommended as a suitable alternative to other first-line ICS/LABA treatments, including FP/SAL and BUD/FORM, by the Midlands Therapeutics Review and Advisory Committee [21] . The Scottish Medicines Consortium has also recommended treatment with FP/FORM in patients for which FP and FORM are appropriate choices of ICS and LABA [22] . The National Institute for Healthcare and Clinical Excellence recommend that for patients in whom treatment with an ICS is considered appropriate, the least costly product should be chosen (within its marketing authorization) [23] . In comparison to FP/SAL, FP/FORM is likely to be the least costly option in terms of list price, and overall budget impact to the NHS. 
